Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHRONYSE:CLDINYSE:CVMNASDAQ:GMDAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHROChromocell Therapeutics$1.26-6.7%$1.15$0.45▼$3.80$8.31M3.27446,134 shs297,097 shsCLDICalidi Biotherapeutics$0.23+2.8%$0.39$0.20▼$3.89$7.31M1.071.00 million shs469,966 shsCVMCEL-SCI$2.29-4.6%$4.66$1.98▼$66.60$6.94M0.2777,160 shs125,680 shsGMDAQGamida Cell$0.02$0.02$0.01▼$2.51$2.62M1.36.58 million shs332,754 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHROChromocell Therapeutics0.00%+17.39%+45.88%-3.36%+2.27%CLDICalidi Biotherapeutics0.00%-20.25%-36.14%-60.49%+22,369,900.00%CVMCEL-SCI0.00%-5.88%+14.29%-65.28%-93.10%GMDAQGamida Cell0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHROChromocell Therapeutics0.4854 of 5 stars0.04.00.00.00.02.50.0CLDICalidi Biotherapeutics0.2065 of 5 stars0.03.00.00.00.60.00.6CVMCEL-SCI0.2007 of 5 stars0.02.00.00.01.50.00.6GMDAQGamida CellN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHROChromocell Therapeutics 0.00N/AN/AN/ACLDICalidi Biotherapeutics 0.00N/AN/AN/ACVMCEL-SCI 0.00N/AN/AN/AGMDAQGamida Cell 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ACLDICalidi Biotherapeutics$50K146.25N/AN/A($2.32) per share-0.10CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AGMDAQGamida Cell$1.78M1.47N/AN/A($0.02) per share-0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ACLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ACVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AGMDAQGamida Cell-$63M-$0.49N/A∞N/AN/AN/A-60.18%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHROChromocell TherapeuticsN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AGMDAQGamida CellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHROChromocell TherapeuticsN/A0.600.60CLDICalidi BiotherapeuticsN/A0.190.19CVMCEL-SCI0.661.071.09GMDAQGamida CellN/A0.350.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHROChromocell Therapeutics77.96%CLDICalidi Biotherapeutics12.53%CVMCEL-SCI12.08%GMDAQGamida Cell50.34%Insider OwnershipCompanyInsider OwnershipCHROChromocell Therapeutics16.40%CLDICalidi Biotherapeutics6.70%CVMCEL-SCI9.93%GMDAQGamida Cell6.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHROChromocell Therapeutics46.60 million5.04 millionN/ACLDICalidi Biotherapeutics3831.79 million20.04 millionN/ACVMCEL-SCI433.03 million64.67 millionOptionableGMDAQGamida CellN/A154.05 million143.70 millionOptionableGMDAQ, CHRO, CVM, and CLDI HeadlinesRecent News About These CompaniesAplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline | DelveInsightMay 15, 2025 | theglobeandmail.comRoslinCT and Ayrmid Pharma Intend to Partner to Manufacture FDA-Approved Cell Therapy OmisirgeMarch 11, 2025 | genengnews.comGGamida Cell Ltd. (GMDAQ)May 16, 2024 | finance.yahoo.comGamida Cell has a second chance to be an Israeli success storyMay 12, 2024 | msn.comGMDAQ Gamida Cell Ltd.May 8, 2024 | seekingalpha.comGamida Cell Ltd.April 10, 2024 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGMDAQ, CHRO, CVM, and CLDI Company DescriptionsChromocell Therapeutics NYSE:CHRO$1.26 -0.09 (-6.67%) As of 04:00 PM EasternChromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Calidi Biotherapeutics NYSE:CLDI$0.23 +0.01 (+2.82%) As of 04:00 PM EasternCalidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.CEL-SCI NYSE:CVM$2.29 -0.11 (-4.58%) As of 04:00 PM EasternCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Gamida Cell NASDAQ:GMDAQGamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
